HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Convinced: Cosmetic Adverse Event Reports Aren’t Telling Whole Story

Executive Summary

Linda Katz, director of the FDA’s cosmetics office, says to “stay tuned” for federal legislative developments in 2022, maintaining her position that voluntary adverse-event reporting paints an incomplete picture of consumers’ experience with cosmetic products across the US.

You may also be interested in...



Attorneys On Modernized Cosmetic Regulations And New Litigation Risks

Greenberg Traurig and Hogan Lovells attorneys provide first breakdowns of the game-changing Modernization of Cosmetic Regulations Act, including the potential for new lawsuits and plaintiff tactics.

ICCR-15: International Cosmetics Regulator Group Tackles Consumer Safety Perceptions

The International Cooperation on Cosmetics Regulations continues efforts to minimize barriers to international trade through regulatory convergence, while also taking steps to educate consumers on cosmetics safety issues that may be widely misunderstood. Personal Care Products Council leadership discusses developments from the regulator group’s 15th annual meeting in June.

US Cosmetics Reform Bill Would Require FDA Regulation Of ‘Natural’ Labeling

Beautycounter and Burt’s Bees are among the most vocal companies pushing for modernization of US cosmetics regulations via the proposed Personal Care Products Safety Act, which would require the FDA to establish a “natural” definition for use in product labeling.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151936

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel